Europe's industry calls for no revision of Transparency Directive, and confidentiality
This article was originally published in Scrip
Reopening the "Transparency Directive," must not compromise the confidentiality of pricing arrangements between pharmaceutical companies and payers, Richard Bergström, director general of the European Federation of the Pharmaceutical Industries and Associations (EFPIA) told Scrip. Revealing details of such agreements would prevent differential pricing, he said.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.